Analyst Price Target is $4.75
▲ +343.93% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Vaxart in the last 3 months. The average price target is $4.75, with a high forecast of $8.00 and a low forecast of $1.50. The average price target represents a 343.93% upside from the last price of $1.07.
Current Consensus is
Buy
The current consensus among 3 polled investment analysts is to buy stock in Vaxart. This Buy consensus rating has held steady for over two years.
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.
Read More